O uso de canabidiol como terapia complementar no transtorno do espectro autista

Abstract

Although there is no clear evidence on the causes of Autistic Spectrum Disorder (ASD), its incidence has increased significantly worldwide. Currently, it is considered a chronic and complex neurodevelopmental pathology, resulting from cerebral dysfunction of unknown multifactorial etiology, which has always made it difficult to identify its etiology in each patient. Thus, the priority treatment is symptomatic and Cannabidiol (CBD) presents itself as a complementary therapy that obtained positive performance in the control of ASD in clinical and laboratory trials. The objective of this study was to describe the use of Cannabidiol as a complementary therapy for the symptoms of ASD. Methodology: This research is characterized as a narrative bibliographic review. Results: Although cannibinoids have shown promising results in the effects of some behavioral symptoms of ASD, such as sleep disorders, seizures and hyperactivity, the influence on essential symptoms, such as deficiency in social communication, restricted and stereotypical interests , remains unknown. Conclusion: Although medical cannabis appears to show promise in addressing core ASD symptoms,evidence-based recommendations are necessary to ensure safety and effectiveness. There is a need for more long-term studies, with homogeneous samples in terms of age, use of medications, level of functioning and presence / absence of seizures. It would be of great importance to choose specific primary and secondary outcomes, focusing on the set of symptoms that could benefit from the use of cannabinoids.